Dermatology

Pediatric dermatology faces access disparities due to lack of awareness, language barriers, and training gaps in recognizing diverse skin conditions.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.

Hadar Avihai Lev-Tov, MD, argues that integrating dermatologists into multidisciplinary health care teams is crucial for providing comprehensive patient care.

The efficacy and safety of both approved and investigational drugs for moderate to severe hidradenitis suppurativa offer valuable evidence to guide clinical decision-making in a field where head-to-head trials are largely absent.

Hadar Avihai Lev-Tov, MD, advocates for a holistic approach to wound care, emphasizing that chronic ulcers often signal underlying systemic health issues requiring a comprehensive patient assessment to achieve effective and potentially life-saving treatment.

Hadar Avihai Lev-Tov, MD, asserts that advancements in teledermatology and artificial intelligence (AI)–powered diagnostic tools are crucial for improving health care efficiency and patient access within managed care.

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic conditions.

Pediatric patients with hidradenitis suppurativa have a significantly increased prevalence of chronic medical and psychiatric comorbidities, highlighting the critical need for comprehensive screening and multidisciplinary care.

Vitiligo Awareness Month and World Vitiligo Day aim to educate the public about the autoimmune skin condition's complex epidemiology, subtypes, mental health impacts, and diverse treatments.

Implementing LGBTQ+ inclusive language in patient care and clinical trials for dermatology could improve data accuracy, relevance, and patient-clinician relationships.

Alopecia areata cases increased from 1990 to 2021, highlighting the need for further research into socioeconomic factors and disease burden.

Significant differences in gut microbiome composition were found among pediatric patients with hidradenitis suppurativa, suggesting further investigation surrounding gut microbiome dysregulation.

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted and effective treatments, though further research is needed to confirm their safety, efficacy, and optimal use.

Air pollution significantly contributes to and worsens various dermatologic conditions through oxidative stress, inflammation, and disruption of the skin barrier.

There are significant environmental impacts of dermatological practices that call for interdisciplinary collaboration and policy changes to promote sustainability and reduce carbon emissions within the field.

As skin cancer rates continue to rise, here are 5 key facts every health care professional should know to improve prevention, early detection, and patient outcomes.

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line treatment for moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers to accessing health care.

Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.